Dual inhibition of the epidermal growth factor and vascular endothelial growth factor phosphorylation for antivascular therapy of human prostate cancer in the prostate of nude mice

Yazici, MUSTAFA; Kim, SJ; Busby, JE; He, J; Thaker, P; Yokoi, K; Fan, D; Fidler, IJ

doi:10.1002/pros.20283

Dual inhibition of the epidermal growth factor and vascular endothelial growth factor phosphorylation for antivascular therapy of human prostate cancer in the prostate of nude mice

Yazici S., Kim S., Busby J., He J., Thaker P., Yokoi K., ...Daha Fazla

PROSTATE, cilt.65, sa.3, ss.203-215, 2005 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 65 Sayı: 3
Basım Tarihi: 2005
Doi Numarası: 10.1002/pros.20283
Dergi Adı: PROSTATE
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.203-215
Anahtar Kelimeler: prostate cancer, EGF-R and VEGF-R phosphorylation, antivascular therapy, RECEPTOR TYROSINE KINASE, CELL LUNG-CANCER, MICROVASCULAR HYPERPERMEABILITY, CLINICAL-SIGNIFICANCE, EGF RECEPTOR, TUMOR-CELLS, EXPRESSION, ANGIOGENESIS, PROGRESSION, BLOCKADE
Hacettepe Üniversitesi Adresli: Evet

Özet

BACKGROUND. Androgen-independent prostate cancer (PCa) may be susceptible to modulation of the tumor microenvironment. We determined whether a dual tyrosine kinase inhibitor (AEE788) of the epidermal growth factor receptor (EGF-R) and vascular endothelial growth factor receptor (VEGF-R) combined with chemotherapy can produce therapy of human PCa in nude mice.